SCHEMBL3013002

SCHEMBL3013002

COc1ccccc1Cc1csc(N2CCC(S(=O)(=O)c3ccc(Br)cc3)CC2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.38
LMNA P02545 1/20 0.38
HTR6 P50406 1/20 0.37
TP53 P04637 1/20 0.36
DRD2 P14416 3/20 0.35
DRD4 P21917 3/20 0.35
DRD3 P35462 3/20 0.35
ALDH1A1 P00352 2/20 0.35
GBA1 P04062 1/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 4/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
CCR3 P51677 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015070 0.92 GBA1 (0.43) SMN1; SMN2LMNAHTR6TP53ALDH1A1
SCHEMBL3006479 0.92 MAPT (0.40) LMNAHTR6DRD2ALDH1A1GBA1
SCHEMBL3019118 0.92 MAPT (0.41) SMN1; SMN2LMNATP53DRD2ALDH1A1
SCHEMBL3005203 0.91 LTA4H (0.36) LMNAALDH1A1GBA1MEN1KMT2A
SCHEMBL2999879 0.90 PSMD14 (0.37) DRD2DRD4DRD3MEN1KMT2A
SCHEMBL3007549 0.89 EDNRA (0.38) ALDH1A1GBA1MEN1KMT2AMAPT
SCHEMBL3019256 0.89 TSHR (0.39) SMN1; SMN2LMNATP53DRD2ALDH1A1
SCHEMBL3007694 0.89 MAPT (0.41) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
SCHEMBL3007192 0.89 SMN1; SMN2 (0.38) SMN1; SMN2LMNAHTR6TP53DRD2
SCHEMBL3010966 0.89 MAPT (0.38) SMN1; SMN2LMNAHTR6TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885LMNA 80/4885HTR6 1988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.